India has achieved a significant milestone in the medical goods business, becoming a net exporter of medical consumables and disposables for the first time in the fiscal year 2022-23.This marks a reversal of an old trend where imports of such products outweighed exports.
Status of India’s Pharmaceutical Industry
- India has historically been dependent on imports for medical consumables and disposables. India has now reversed this trend, indicating a shift towards self-sufficiency in this sector.
- India is the largest manufacturer of generic medicines globally. Its pharmaceutical industry plays a crucial role in global healthcare, providing affordable generic medicines.
- It is currently valued at USD 50 billion as a major pharmaceutical exporter, with over 200+ countries served by Indian pharma exports.
- It is expected to reach USD 65 Billion by 2024 and to USD 130 Billion by 2030.
Export and Import Statistics
- Exports: India exported medical consumables and disposables worth USD 1.6 billion, showing a 16% surge over the previous fiscal year (2021-22).
- Imports: Imports amounted to approximately USD 1.1 billion, indicating a 33% decline.
Major Challenges with India’s Pharma Sector
- Lagging Research and Development (R&D): India’s R&D spending in pharma is lower compared to developed nations. This hinders the creation of new drugs.
- Limited Innovation Ecosystem: Collaboration between academia, research institutions, and pharmaceutical companies is weak, slowing down development of high qualtity drugs and medical devices.
- Price Controls and Profit Margins: Government price controls on some drugs can limit profits, making it less attractive for companies to invest heavily in R&D for new drugs.
- Complex Regulatory Framework: Navigating the approval process for new drugs can be lengthy and complex which leads to red tapism.
- Skilled Workforce Shortage: There’s a lack of highly qualified scientists and researchers in the pharma sector, which leads to overburdened staff affecting efficiency.
- Intellectual Property (IP) Concerns: Uncertainties around IP protection, due to provisions like compulsory licensing (Indian Patents Act 1970), can discourage large pharma investment in India.
- Import Dependency: Despite progress, India remains largely dependent on imports for medical devices, with around 70% sourced from other nations.
- India’s heavy dependence on Active Pharmaceutical Ingredients (APIs) imports, particularly from countries like China.
- Substandard Drugs: One significant issue in the Indian pharmaceutical sector is the occurrence of deaths linked to the consumption of substandard or counterfeit drugs.
- Indian-origin medicines leads to multiple deaths of children in Africa and Central Asia.